In line with PI3K/mTOR inhibitors, various kinase inhibitors have entered into clinical trials for gastrointestinal cancers [194], thyroid carcinoma [195], breast cancer [196], and endocrine tumors [197]. This evidence concerns the gene MTOR and breast cancer.